Pharmacologic interventions for weight-related health risks
Evidence-based guidelines for obesity support the use of pharmacologic therapy in collaboration with lifestyle interventions.
Evidence-based guidelines for obesity support the use of pharmacologic therapy in collaboration with lifestyle interventions.
The first step in reducing the risk of cardiovascular disease is for health-care professionals to get a full understanding of a patient’s risk.
Approximately two-thirds of patients with Parkinson disease and depression were not taking an antidepressant at any visit.
One study of 6,459 U.S. women aged 55 years to 81 years revealed that the use of alendronate or placebo did not affect the proportion of women who developed breast cancer (1.8% and 1.5%, respectively).
Primary-care practitioners should change to accommodate patients seeking primary care from emergency departments.
Doctors should start a dialogue about advance directives upon a patient’s first visit to help them make decisions regarding their health care.
An obese patient with chronic hepatitis C, diabetes, advanced cirrhosis, and fatty pancreas presents with chronic right-to-middle upper-abdomen pain.
Due to the limited amount of high-quality human studies, craniosacral therapy should not be suggested as a first-line treatment.
Compared with patients who had not taken statins, those who had were less likely to develop diabetic neuropathy by 34%, diabetic retinopathy by 40%, and gangrene by 12%.
Patient with back pain and blood in urine is diagnosed with autosomal dominant polycystic kidney disease.